We are live on ! Find out more
PBA

Paradigm Biocapital Advisors Portfolio holdings

AUM $4.89B
1-Year Est. Return 251.12%
This Fund
S&P 500
This Quarter Est. Return
-11.56%
1 Year Est. Return
+251.12%
3 Year Est. Return
+670.11%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.18B
AUM Growth
-$691M
Cap. Flow
-$226M
Cap. Flow %
-10.34%
Top 10 Hldgs %
76.03%
Holding
34
New
6
Increased
11
Reduced
10
Closed
6

Top Buys

Rank Stock Value
1
MRUS
Merus
MRUS
+$73.2M
2
CYTK icon
Cytokinetics
CYTK
+$39.5M
3
INSM icon
Insmed
INSM
+$34.5M
4
MTSR
Metsera Inc
MTSR
+$33.8M
5
COGT icon
Cogent Biosciences
COGT
+$31.7M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$266M
2
VERA icon
Vera Therapeutics
VERA
+$60.8M
3
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$49.3M
4
PLRX icon
Pliant Therapeutics
PLRX
+$42.1M
5
TECX
Tectonic Therapeutic
TECX
+$22.4M

Sector Composition

Rank Sector Weight
1 Healthcare 99.5%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NUVL
1
DELISTED
Nuvalent
NUVL
$374M 17.12%
5,269,433
-93,946
-2% -$7.35M
ACLX
2
DELISTED
Arcellx
ACLX
$295M 13.5%
4,492,032
+120,431
+3% +$8.16M
RVMD icon
3
Revolution Medicines
RVMD
$40.2B
$218M 10.01%
6,178,111
-375,000
-6% -$15.2M
ONC
4
BeOne Medicines Ltd
ONC
$33.8B
$181M 8.3%
666,024
+50,000
+8% +$11.7M
MRUS
5
DELISTED
Merus
MRUS
$142M 6.5%
3,369,699
+1,679,777
+99% +$73.2M
TARS icon
6
Tarsus Pharmaceuticals
TARS
$2.56B
$134M 6.14%
2,610,197
+78,301
+3% +$3.87M
EWTX icon
7
Edgewise Therapeutics
EWTX
$4.39B
$96.7M 4.43%
4,394,556
-99,373
-2% -$2.61M
JANX icon
8
Janux Therapeutics
JANX
$935M
$89.9M 4.12%
3,329,909
-186,077
-5% -$7.01M
CRNX icon
9
Crinetics Pharmaceuticals
CRNX
$8.86B
$65.3M 2.99%
1,946,168
+35,407
+2% +$1.32M
PCVX icon
10
Vaxcyte
PCVX
$7.89B
$64.1M 2.93%
1,696,481
+273,694
+19% +$21.9M
IRON icon
11
Disc Medicine
IRON
$2.83B
$60.1M 2.75%
1,210,971
-286,749
-19% -$15.9M
COGT icon
12
Cogent Biosciences
COGT
$6.79B
$53.7M 2.46%
8,963,655
+4,046,243
+82% +$31.7M
LENZ
13
LENZ Therapeutics
LENZ
$172M
$38.9M 1.78%
1,511,932
+741,477
+96% +$18.3M
APGE icon
14
Apogee Therapeutics
APGE
$10.2B
$35.9M 1.65%
961,707
-322,059
-25% -$12.5M
ARGX icon
15
argenx
ARGX
$57.4B
$35.3M 1.62%
59,679
-421,626
-88% -$266M
CYTK icon
16
Cytokinetics
CYTK
$11B
$34.5M 1.58%
+858,664
New +$39.5M
INSM icon
17
Insmed
INSM
$23.2B
$34.4M 1.58%
+451,359
New +$34.5M
SYRE icon
18
Spyre Therapeutics
SYRE
$8.87B
$34.3M 1.57%
2,127,205
+600,000
+39% +$12.5M
MTSR
19
DELISTED
Metsera Inc
MTSR
$32.4M 1.49%
+1,191,462
New +$33.8M
VRDN icon
20
Viridian Therapeutics
VRDN
$2.13B
$28.2M 1.29%
2,095,079
+275,000
+15% +$4.68M
OLMA icon
21
Olema Pharmaceuticals
OLMA
$1.02B
$25.3M 1.16%
6,741,172
-563,798
-8% -$2.84M
MLTX icon
22
MoonLake Immunotherapeutics
MLTX
$1.59B
$24.5M 1.12%
627,423
-1,144,788
-65% -$49.3M
ARQT icon
23
Arcutis Biotherapeutics
ARQT
$3.42B
$22.9M 1.05%
+1,465,334
New +$20.6M
YMAB
24
DELISTED
Y-mAbs Therapeutics
YMAB
$18.8M 0.86%
4,236,346
– –
ERAS icon
25
Erasca
ERAS
$6.63B
$14.8M 0.68%
10,802,354
+50,000
+0.5% +$85.8K
1
2

Similar funds

KCM
Kensico Capital Management Greenwich, Connecticut $4.9B AUM 41.26% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
FC
Freemont Capital Singapore $4.91B AUM 5.45% 1-Year Est. Return
WTC
WhitTier Trust Company Reno, Nevada $4.87B AUM 25.35% 1-Year Est. Return
MCM
Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return
MSRPS
Maryland State Retirement & Pension System Baltimore, Maryland $4.92B AUM 28.48% 1-Year Est. Return
MCCA
Mill Creek Capital Advisors Conshohocken, Pennsylvania $4.87B AUM 17.69% 1-Year Est. Return
SIA
Sit Investment Associates Minneapolis, Minnesota $4.93B AUM 12.22% 1-Year Est. Return

Paradigm Biocapital Advisors's Q1 2025 Portfolio in Review

As of Q1 2025, Paradigm Biocapital Advisors held 34 positions worth $2.18B, down 24% from $2.87B the previous quarter. Its ten largest holdings account for 76% of the portfolio.

Paradigm Biocapital Advisors withdrew a net $226M in Q1 2025, closing 6 positions and reducing 10 holdings. Its most notable exit was Vera Therapeutics, an estimated $60.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier.

Against the trend, Paradigm Biocapital Advisors opened a new position in Cytokinetics worth $34.5M.

  • Paradigm Biocapital Advisors's largest Q1 2025 buy was Cytokinetics: 858,664 shares worth $34.5M.
  • Paradigm Biocapital Advisors added most to Merus in Q1 2025, an estimated $73.2M increase.
  • Paradigm Biocapital Advisors's biggest Q1 2025 reduction was argenx, cutting an estimated $266M.
  • Paradigm Biocapital Advisors fully exited Vera Therapeutics in Q1 2025, selling an estimated $60.8M.
  • Paradigm Biocapital Advisors's ten largest holdings make up 76% of its $2.18B portfolio in Q1 2025.
  • Paradigm Biocapital Advisors opened 6 new positions and closed 6 in Q1 2025.
  • Paradigm Biocapital Advisors's portfolio value fell 24% quarter-over-quarter to $2.18B.

Based on Paradigm Biocapital Advisors's 13F filing for Q1 2025, filed 15 May 2025.